Literature DB >> 22251940

Cyclin D1-negative blastoid mantle cell lymphoma identified by SOX11 expression.

Weifen Zeng1, Kai Fu, Leticia Quintanilla-Fend, Megan Lim, Sarah Ondrejka, Eric D Hsi.   

Abstract

SOX11 expression has been recently shown to be useful in the diagnosis of mantle cell lymphoma (MCL), including cyclin D1-negative MCL with typical morphology. We evaluated SOX11 expression pattern in B-cell non-Hodgkin lymphoma (B-NHL) subtypes to confirm specificity and used it as a feature to identify the first reported cases of cyclin D1-negative blastoid MCL. SOX11 expression was evaluated by immunohistochemistry in 140 cases of mature B-NHL, including 4 cases of suspected blastoid MCL that lacked cyclin D1 expression and 8 cases of CD5-positive diffuse large B-cell lymphoma (DLBL). In addition, 5 cases of B or T lymphoblastic lymphoma were included. Nuclear expression of SOX11 was found in cyclin D1-positive MCL (30/30, 100%) and in a case of cyclin D1-negative MCL with typical morphology. SOX11 was also expressed in Burkitt lymphoma (1/5, 20%) and lymphoblastic lymphoma (2/3 T-LBLs, 2/2 B-LBLs, overall 4/5, 80%), whereas all cases of DLBL (including CD5 DLBL) and other small B-NHL were negative. The 4 suspected cases of blastoid MCL were also SOX11. These cases had a complex karyotype that included 12p abnormalities. We confirmed prior reports that stated that SOX11 nuclear expression was a specific marker for MCL, including cyclin D1-negative MCL with typical morphology. To our knowledge, this is the first report regarding its use in identifying cases of cyclin D1-negative blastoid MCL. Routine use of SOX11 in cases of suspected CD5 DLBL might help identify additional cases of cyclin D1-negative blastoid MCL.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22251940     DOI: 10.1097/PAS.0b013e318241f050

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  14 in total

1.  The role of tumor suppressor gene SOX11 in prostate cancer.

Authors:  Zhiyong Yao; Bin Sun; Quan Hong; Jingmin Yan; Dawei Mu; Jianye Li; Haibo Sheng; Heqing Guo
Journal:  Tumour Biol       Date:  2015-03-14

2.  CCND2 rearrangements are the most frequent genetic events in cyclin D1(-) mantle cell lymphoma.

Authors:  Itziar Salaverria; Cristina Royo; Alejandra Carvajal-Cuenca; Guillem Clot; Alba Navarro; Alejandra Valera; Joo Y Song; Renata Woroniecka; Grzegorz Rymkiewicz; Wolfram Klapper; Elena M Hartmann; Pierre Sujobert; Iwona Wlodarska; Judith A Ferry; Philippe Gaulard; German Ott; Andreas Rosenwald; Armando Lopez-Guillermo; Leticia Quintanilla-Martinez; Nancy L Harris; Elaine S Jaffe; Reiner Siebert; Elias Campo; Sílvia Beà
Journal:  Blood       Date:  2012-12-18       Impact factor: 22.113

3.  CD5 positivity is an independent adverse prognostic factor in elderly patients with diffuse large B cell lymphoma.

Authors:  Wen-Yu Chuang; Hung Chang; Lee-Yung Shih; Po-Nan Wang; Yu-Sun Chang; Tung-Liang Lin; Yu-Shin Hung; Chi-Ju Yeh; Shir-Hwa Ueng; Tzung-Chih Tang; Ming-Chung Kuo; Po Dunn; Jin-Hou Wu; Hsiao-Wen Kao; Che-Wei Ou; Yung-Liang Wan; Chuen Hsueh
Journal:  Virchows Arch       Date:  2015-09-14       Impact factor: 4.064

4.  SOX11 augments BCR signaling to drive MCL-like tumor development.

Authors:  Pei-Yu Kuo; Shashidhar S Jatiani; Adeeb H Rahman; Donna Edwards; Zewei Jiang; Katya Ahr; Deepak Perumal; Violetta V Leshchenko; Joshua Brody; Rita Shaknovich; B Hilda Ye; Samir Parekh
Journal:  Blood       Date:  2018-04-03       Impact factor: 22.113

5.  Non-Hodgkin's lymphomas, version 4.2014.

Authors:  Andrew D Zelenetz; Leo I Gordon; William G Wierda; Jeremy S Abramson; Ranjana H Advani; C Babis Andreadis; Nancy Bartlett; John C Byrd; Myron S Czuczman; Luis E Fayad; Richard I Fisher; Martha J Glenn; Nancy Lee Harris; Richard T Hoppe; Steven M Horwitz; Christopher R Kelsey; Youn H Kim; Susan Krivacic; Ann S LaCasce; Auayporn Nademanee; Pierluigi Porcu; Oliver Press; Rachel Rabinovitch; Nishitha Reddy; Erin Reid; Ayman A Saad; Lubomir Sokol; Lode J Swinnen; Christina Tsien; Julie M Vose; Joachim Yahalom; Nadeem Zafar; Mary Dwyer; Hema Sundar
Journal:  J Natl Compr Canc Netw       Date:  2014-09       Impact factor: 11.908

6.  Expanded clinical and experimental use of SOX11 - using a monoclonal antibody.

Authors:  Lena Nordström; Ulrika Andréasson; Mats Jerkeman; Michael Dictor; Carl Borrebaeck; Sara Ek
Journal:  BMC Cancer       Date:  2012-06-27       Impact factor: 4.430

7.  The metastasis suppressor SOX11 is an independent prognostic factor for improved survival in gastric cancer.

Authors:  Ying Qu; Chenfei Zhou; Jianian Zhang; Qu Cai; Jianfang Li; Tao Du; Zhenggang Zhu; Xiaojiang Cui; Bingya Liu
Journal:  Int J Oncol       Date:  2014-03-06       Impact factor: 5.650

8.  Clinicopathologic features of 112 cases with mantle cell lymphoma.

Authors:  Dong-Mei Zhou; Gang Chen; Xiong-Wei Zheng; Wei-Feng Zhu; Bao-Zhen Chen
Journal:  Cancer Biol Med       Date:  2015-03       Impact factor: 4.248

9.  SOX11 Inhibitors Are Cytotoxic in Mantle Cell Lymphoma.

Authors:  Shashidhar S Jatiani; Stephanie Christie; Violetta V Leshchenko; Rinku Jain; Abhijeet Kapoor; Paola Bisignano; Clement Lee; H Ümit Kaniskan; Donna Edwards; Fanye Meng; Alessandro Laganà; Youssef Youssef; Adrian Wiestner; Lapo Alinari; Jian Jin; Marta Filizola; Aneel K Aggarwal; Samir Parekh
Journal:  Clin Cancer Res       Date:  2021-06-22       Impact factor: 12.531

Review 10.  The pathologic diagnosis of mantle cell lymphoma.

Authors:  Shaoying Li; Jie Xu; M James You
Journal:  Histol Histopathol       Date:  2021-06-11       Impact factor: 2.303

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.